Key result
Troglitazone attenuated or prevented high-glucose-induced prolongation of relaxation and abnormally slow rates of Ca2+ transient decay in cultured rat ventricular myocytes.
Why the study?
Does troglitazone prevent high-glucose-induced relaxation defects and abnormal Ca2+ transient decay in isolated rat ventricular myocytes?
Population
Normal adult rat ventricular myocytes maintained in culture
Comparison
Troglitazone added to high-glucose medium for… vs High-glucose medium without troglitazone, and…
Design
Preclinical
Follow-up
1-2 days
Authors
Loading...
May support direct myocardial protection by troglitazone in hyperglycemia; leaves open translation to in vivo or human diabetes.
Does troglitazone prevent high-glucose-induced relaxation defects and abnormal Ca2+ transient decay in isolated rat ventricular myocytes?
Troglitazone protects against high-glucose-induced relaxation defects and abnormal calcium handling in isolated rat ventricular myocytes, suggesting potential direct beneficial cardiac properties in diabetes.
Ren et al. (1996) studied High-glucose-induced cardiac dysfunction. Troglitazone vs. High-glucose medium without troglitazone was evaluated on Mechanical properties (relaxation from peak contraction) and Ca2+ transients. Troglitazone attenuated or prevented high-glucose-induced prolongation of relaxation and abnormally slow rates of Ca2+ transient decay in cultured rat ventricular myocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: